Squibb/Novo-Nordisk
Executive Summary
CNS drug development and co-marketing agreement, announced by Squibb May 2, expands relationship between the firms beyond insulin to central nervous system disease therapies for depression, anxiety and psychosis. The deal was signed in first quarter and announced by Squibb at its annual meeting. In depression area, Novo-Nordisk has been working on dopamine reuptake inhibitors. GBR-12909 is currently in Phase II clinicals in Europe. Other CNS compounds are: FD- 10571, a non-benzodiazapine anxiolytic; FG-8119, a partial benzodiazapine receptor agonist; and fexometine,a 5-HT reuptake inhibitor with antidepressant properties.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.